Home » Stocks » UROV

Urovant Sciences Ltd. (UROV)

Stock Price: $16.16 USD 0.01 (0.06%)
Updated Jan 21, 2021 12:20 PM EST - Market open
Market Cap 512.29M
Revenue (ttm) n/a
Net Income (ttm) -158.17M
Shares Out 31.25M
EPS (ttm) -5.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $16.16
Previous Close $16.15
Change ($) 0.01
Change (%) 0.06%
Day's Open 16.15
Day's Range 16.15 - 16.17
Day's Volume 5,012
52-Week Range 7.16 - 16.19

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 3 weeks ago

NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Urovant Sciences Ltd. (NASDAQ: UROV) concern...

GlobeNewsWire - 4 weeks ago

GEMTESA® is the second FDA approval for the Sumitovant Biopharma family of companies in the past weekGEMTESA® is the first new oral branded OAB medication approved by the U.S. FDA since 2012 a...

Business Wire - 4 weeks ago

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (ND...

Business Wire - 1 month ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Urovant ...

Business Wire - 1 month ago

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--UROV Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary ...

Business Wire - 2 months ago

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 18, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://or...

PRNewsWire - 2 months ago

BERWYN, Pa., Nov. 18, 2020 /PRNewswire/ -- RM LAW, P.C. announces an investigation on behalf of Urovant Sciences Ltd. ("Urovant" or the "Company") (NASDAQ: UROV) regarding possible breaches of...

Seeking Alpha - 2 months ago

The acquisition of Urovant Sciences by majority owner Sumitomo significantly undervalues the company's lead asset vibegron. The buyout price implies approximately $250 million in peak sales fo...

PRNewsWire - 2 months ago

NEW YORK, Nov. 13, 2020 /PRNewswire/-- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New...

PRNewsWire - 2 months ago

NEW YORK, Nov. 13, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Urovant Sciences Ltd. ("UROV"...

The Motley Fool - 2 months ago

The company's biggest shareholder plans to acquire all of Urovant.

InvestorPlace - 2 months ago

Urovant Sciences (UROV) has entered into an acquisition agreement with Sumitovant Biopharma that has UROV stock soaring on Friday. The post UROV Stock: 9 Things to Know About the Urovant Scien...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Urovant Sciences Ltd. (NASDAQ: UROV) to Sumitovant Biopharma Ltd. for $16.2...

Business Wire - 2 months ago

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares

PRNewsWire - 2 months ago

NEW YORK and LONDON and IRVINE, Calif. and BASEL, Switzerland, Nov. 12, 2020 /PRNewswire/ -- Sumitovant Biopharma and Urovant Sciences (Nasdaq: UROV) today announced that they have entered int...

Business Wire - 2 months ago

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Present at the Jefferies Virtual London Healthcare Conference

Seeking Alpha - 2 months ago

Urovant Sciences' (UROV) CEO Jim Robinson on Q2 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results

Business Wire - 2 months ago

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results

Business Wire - 3 months ago

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals

Seeking Alpha - 4 months ago

Urovant's valuation is reasonable when compared to the potential sales peak of Vibegron.

Business Wire - 4 months ago

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Present at the H.C.

Seeking Alpha - 5 months ago

Urovant Sciences Ltd. (UROV) CEO James Robinson on Q1 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Reports Fiscal First Quarter 2020 Results

Business Wire - 5 months ago

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results

Seeking Alpha - 7 months ago

Urovant Sciences Ltd (UROV) on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 7 months ago

Urovant Sciences Ltd (UROV) CEO James Robinson on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 7 months ago

Urovant Sciences: Still A Hidden Gem With Multiple Catalysts Approaching

Seeking Alpha - 8 months ago

Urovant Has Upside Potential Heading Into Vibegron's PDUFA Later This Year

Seeking Alpha - 10 months ago

The company has a diversified pipeline in that Vibegron is being explored for several indications that could bring in billions of dollars.

Seeking Alpha - 11 months ago

Urovant Sciences' (UROV) CEO Keith Katkin on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 11 months ago

Urovant Sciences Is A Hidden Gem With A Blockbuster Drug Likely To Be Approved This Year And 'Short Squeeze' Potential. PT: $43

Benzinga - 1 year ago

Urovant Sciences Ltd (NASDAQ: UROV) has submitted a New Drug Application (NDA) to the U.S.

Seeking Alpha - 1 year ago

Urovant Sciences Ltd. (UROV) CEO Keith Katkin on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Urovant Sciences Limited (UROV) CEO Keith Katkin on Q1 2019 Results - Earnings Call Transcript

GuruFocus - 1 year ago

Finisar falls, Urovant Sciences rises on financial results.

Other stocks mentioned: FNSR
Seeking Alpha - 1 year ago

Urovant Sciences Limited (UROV) CEO Keith Katkin on Q4 2018 Results - Earnings Call Transcript

About UROV

Urovant Sciences, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant... [Read more...]

Industry
Biotechnology
IPO Date
Sep 27, 2018
CEO
James A. Robinson Jr.
Employees
70
Stock Exchange
NASDAQ
Ticker Symbol
UROV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for UROV stock is "Hold." The 12-month stock price forecast is 16.17, which is an increase of 0.06% from the latest price.

Price Target
$16.17
(0.06% upside)
Analyst Consensus: Hold